Madrigal Pharmaceuticals
MDGL
257 hedge funds and large institutions have $6.41B invested in Madrigal Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 111 increasing their positions, 64 reducing their positions, and 55 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 64
68% more call options, than puts
Call options by funds: $312M | Put options by funds: $186M
14% more capital invested
Capital invested by funds: $5.64B → $6.41B (+$770M)
1.25% more ownership
Funds ownership: 106.08% → 107.33% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
4% less funds holding
Funds holding: 268 → 257 (-11)
11% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 55
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$362M |
| 2 |
BlackRock
New York
|
+$51.6M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$36.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32.8M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$30.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$54.6M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$52.6M |
| 3 |
PA
Perceptive Advisors
New York
|
-$39.4M |
| 4 |
AG
Artal Group
Luxembourg
|
-$29.5M |
| 5 |
Janus Henderson Group
London,
|
-$27.5M |
MDGL Hedge Fund Activity: Q2 2024 in Review
257 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2024, worth a combined $6.41B — up 14% from $5.64B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of MDGL and 49 opened new positions — a net loss of 6 holders — while 64 trimmed existing stakes and 111 added.
The largest buyer was RTW Investments, adding an estimated $362M. The largest seller was RA Capital Management, exiting entirely with an estimated $54.6M sold.
- 257 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2024, down from 268 in Q1 2024.
- Funds reported $6.41B of Madrigal Pharmaceuticals stock for Q2 2024, up 14% quarter-over-quarter.
- 49 funds opened new Madrigal Pharmaceuticals positions in Q2 2024 and 55 closed out, a net change of -6 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2024 was RTW Investments, an estimated $362M added.
- The largest Madrigal Pharmaceuticals seller in Q2 2024 was RA Capital Management, an estimated $54.6M sold.
Based on aggregated 13F filings for Q2 2024.